Rossana Soloperto

Dr. Rossana Soloperto

Federico II University of Naples
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2017 in Journal of the American Heart Association
Verified
Journal Article
Open access
MPMaurizio Paciaroni
Maurizio Paciaroni
GAGiancarlo Agnelli
Giancarlo Agnelli
NFNicola Falocci
Nicola Falocci
GTGeorgios Tsivgoulis
Georgios Tsivgoulis
KVKostantinos Vadikolias
Kostantinos Vadikolias
VCValeria Caso
Valeria Caso
Background: The optimal timing to administer non–vitamin K oral anticoagulants ( NOAC s) in patients with acute ischemic stroke and atrial fibrillation is unclear. This prospective observational multicenter study evaluated the rates of early recurrence and major bleeding (within 90 days) and their timing in patients with acute ischemic stroke and atrial fibrillation who received NOAC s for secondary prevention. Methods and Results: Recurrence was defined as the composite of ischemic stroke, transient ischemic attack, and symptomatic systemic embolism, and major bleeding was defined as symptomatic cerebral and major extracranial bleeding. For the analysis, 1127 patients were eligible: 381 (33.8%) were treated with dabigatran, 366 (32.5%) with rivaroxaban, and 380 (33.7%) with apixaban. Patients who received dabigatran were younger and had lower admission National Institutes of Health Stroke Scale score and less commonly had a CHA 2 DS 2 ‐ VAS c score >4 and less reduced renal function. Thirty‐two patients (2.8%) had early recurrence, and 27 (2.4%) had major bleeding. The rates of early recurrence and major bleeding were, respectively, 1.8% and 0.5% in patients receiving dabigatran, 1.6% and 2.5% in those receiving rivaroxaban, and 4.0% and 2.9% in those receiving apixaban. Patients who initiated NOAC s within 2 days after acute stroke had a composite rate of recurrence and major bleeding of 12.4%; composite rates were 2.1% for those who initiated NOACs between 3 and 14 days and 9.1% for those who initiated >14 days after acute stroke. Conclusions: In patients with acute ischemic stroke and atrial fibrillation, treatment with NOAC s was associated with a combined 5% rate of ischemic embolic recurrence and severe bleeding within 90 days.

27 April 2024 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
Alberto CorrieroAlberto Corriero
Alberto Corriero
MGMariateresa Giglio
Mariateresa Giglio
RSRossana Soloperto
Rossana Soloperto
Francesco InchingoloFrancesco Inchingolo
Francesco Inchingolo
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
FPFilomena Puntillo
Filomena Puntillo
One of the most common musculoskeletal disorders, osteoarthritis (OA), causes worldwide disability, morbidity, and poor quality of life by degenerating articular cartilage, modifying subchondral bone, and inflaming synovial membranes. OA pathogenesis pathways must be understood to generate new preventative and disease-modifying therapies. In recent years, it has been acknowledged that gut microbiota (GM) can significantly contribute to the development of OA. Dysbiosis of GM can disrupt the “symphony” between the host and the GM, leading to a host immunological response that activates the “gut–joint” axis, ultimately worsening OA. This narrative review summarizes research supporting the “gut–joint axis” hypothesis, focusing on the interactions between GM and the immune system in its two main components, innate and adaptive immunity. Furthermore, the pathophysiological sequence of events that link GM imbalance to OA and OA-related pain is broken down and further investigated. We also suggest that diet and prebiotics, probiotics, nutraceuticals, exercise, and fecal microbiota transplantation could improve OA management and represent a new potential therapeutic tool in the light of the scarce panorama of disease-modifying osteoarthritis drugs (DMOADs). Future research is needed to elucidate these complex interactions, prioritizing how a particular change in GM, i.e., a rise or a drop of a specific bacterial strain, correlates with a certain OA subset to pinpoint the associated signaling pathway that leads to OA.
1

18 March 2024 in Life
Verified
Journal Article
Open access
PDF file
RSRossana Soloperto
Rossana Soloperto
FMFederica MAGNI
Federica MAGNI
AFAnita Farinella
Anita Farinella
EBElisa Gouvêa Bogossian
Elisa Gouvêa Bogossian
Lorenzo PelusoLorenzo Peluso
Lorenzo Peluso
FAfilippo annoni
filippo annoni
We investigated independent factors predicting neurological outcome and death, comparing in-hospital (IHCA) and out-of-hospital cardiac arrest (OHCA) patients. The study was conducted in the mixed 34-bed Intensive Care Department at the Hôpital Universitaire de Bruxelles (HUB), Belgium. All adult consecutive cardiac arrest (CA) survivors were included between 2004 and 2022. For all patients, demographic data, medical comorbidities, CA baseline characteristics, treatments received during Intensive Care Unit stay, in-hospital major complications, and neurological outcome at three months after CA, using the Cerebral Performance Category (CPC) scale, were collected. In the multivariable analysis, in the IHCA group (n = 540), time to return of spontaneous circulation (ROSC), older age, unwitnessed CA, higher lactate on admission, asystole as initial rhythm, a non-cardiac cause of CA, the occurrence of shock, the occurrence of acute kidney injury (AKI), and the presence of previous neurological disease and of liver cirrhosis were independent predictors of an unfavorable neurological outcome. Among patients with OHCA (n = 567), time to ROSC, older age, higher lactate level on admission, unwitnessed CA, asystole or pulseless electrical activity (PEA) as initial rhythm, the occurrence of shock, a non-cardiac cause of CA, and a previous neurological disease were independent predictors of an unfavorable neurological outcome. To conclude, in our large cohort of mixed IHCA and OHCA patients, we observed numerous factors independently associated with a poor neurological outcome, with minimal differences between the two groups, reflecting the greater vulnerability of hospitalized patients.

17 June 2025 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
Alberto CorrieroAlberto Corriero
Alberto Corriero
MGMariateresa Giglio
Mariateresa Giglio
RSRossana Soloperto
Rossana Soloperto
APAngela Preziosa
Angela Preziosa
CSCristina Stefanelli
Cristina Stefanelli
FPFilomena Puntillo
Filomena Puntillo
Cancer-related pain (CrP) is one of the most frequent and debilitating issues that affect the quality of life of patients with cancer. Systemic analgesics, particularly opioids, have been the cornerstone of pain management. However, the following shortcomings of the mentioned therapies, such as side effects, tolerance, and inadequate relief in refractory cases, make implementing a more complete, multimodal treatment plan necessary. Interventional pain management (IPM) uses specific invasive procedures, with different degree of invasiveness, such as nerve blocks, neurolysis, neuromodulation, and intrathecal drug delivery systems to provide effective pain relief with reduced adverse effects compared with opioids. These approaches are frequently underutilized due to delayed referrals, insufficient awareness, and logistic inefficiencies, which delay access to pain management centers specializing in care for patients in pain. Recent technological advancements offer the potential to overcome these barriers, including artificial intelligence-driven decision support systems and automated referral pathways, enabling early intervention and individualized pain treatment plans. The future of CrP management should shift from the current reactive model to a proactive approach, enabling the earlier incorporation of interventional techniques into treatment plans. The integration of interdisciplinary collaboration and technological innovations will enhance cancer pain management and progress from current outdated approaches to provide more effective and timely pain relief for patients with chronic refractory cancer pain.

18 March 2024 in Advancements in Health Research
Verified
Journal Article
Open access
PDF file
Alberto CorrieroAlberto Corriero
Alberto Corriero
MGMariateresa Giglio
Mariateresa Giglio
RSRossana Soloperto
Rossana Soloperto
Giustino VarrassiGiustino Varrassi
Giustino Varrassi
FPFilomena Puntillo
Filomena Puntillo
Art therapy, dance therapy, and music therapy have emerged as complementary and integrative approaches to healthcare, providing powerful avenues for healing, growth, and self-discovery. This narrative review explores the multifaceted role of these therapeutic interventions, examining their mechanisms, applications, and evidence-based benefits in promoting health and well-being across diverse populations and clinical settings. Music therapy has been shown to have a range of applications in healthcare, particularly in improving the general ambience of hospital settings. Dance therapy, also known as dance/movement therapy (DMT), harnesses the therapeutic power of movement to improve physical, emotional, cognitive, and social needs. Integrating art therapy into healthcare settings supports patient healing and well-being and enhances the working environment for healthcare providers. These new integrative approaches in healthcare settings offer benefits such as enjoyment, satisfaction, improvements in health and wellbeing, social connections, and relaxation for participants.
1

10 November 2025 in Trials
Verified
Journal Article
Open access
PDF file
Alberto CorrieroAlberto Corriero
Alberto Corriero
RSRossana Soloperto
Rossana Soloperto
MGMariateresa Giglio
Mariateresa Giglio
Michele SalvagnoMichele Salvagno
Michele Salvagno
PTPaolo Trerotoli
Paolo Trerotoli
VRVito Marco Ranieri
Vito Marco Ranieri
Ventilator-associated pneumonia (VAP) remains a significant complication among critically ill patients, with associated mortality approaching 50%. Despite the implementation of established preventive strategies, additional interventions are urgently needed to further reduce the incidence of VAP. Probiotic therapy has emerged as a promising adjunctive approach; the benefits of probiotic therapy may be more pronounced in critically ill patients without pre-existing infections. The PROACT study will evaluate the prophylactic role of probiotics in a critically ill population with acute brain injury to reduce the VAP incidence, while also exploring microbiological endpoints and mortality to refine patient selection criteria. The PROACT study is a prospective, randomized, double-blind, placebo-controlled, multicenter trial designed to evaluate the efficacy of probiotic prophylaxis in adult critically ill patients requiring invasive mechanical ventilation following acute brain injury (e.g., head trauma, ischemic or hemorrhagic stroke). Patients with suspected pulmonary aspiration or pre-existing pulmonary infections at enrollment are excluded to reduce confounding. Participants are randomized in a 1:1 ratio to receive either a placebo (glucose polymer) or a probiotic formulation containing Lactobacillus acidophilus LA-5, Lactobacillus plantarum, Bifidobacterium lactis BB12, and Saccharomyces boulardii. The assigned intervention is administered twice daily via nasogastric tube and oropharyngeal application for up to 30 days or until intensive care unit (ICU) discharge. The primary endpoint is the incidence of VAP, as defined by current international guidelines, in the intention-to-treat (ITT) population. Secondary endpoints include the incidence of VAP in the modified intention-to-treat (mITT) population, catheter-related bloodstream infections, occurrence of sepsis and septic shock, 30-day all-cause mortality, ICU length of stay, and duration of mechanical ventilation. The study is powered at 80% (α = 0.05) to detect a clinically meaningful difference based on effect size estimates based on the PROVAP study, requiring a total sample size of 208 patients. All participating centers implement standard VAP prevention bundles as part of routine care. By evaluating the efficacy of probiotic therapy in preventing VAP and the impact on mortality among critically ill brain-injured patients, this trial has the potential to generate high-quality evidence supporting the incorporation of probiotics into standard VAP prevention protocols. The findings may have significant implications for clinical practice guidelines and public health policy related to infection control and microbiome-targeted interventions in the intensive care setting. Registered at ClinicalTrials.gov (identifier: [NCT06092554]). Registered on 2023-10-15.